95 related articles for article (PubMed ID: 11326658)
1. Tissue polypeptide specific antigen serum concentrations in patients with newly diagnosed prostatic diseases.
Wolff JM; Rohde D; Borchers H; Jakse G
Anticancer Res; 2000; 20(6D):5003-5. PubMed ID: 11326658
[TBL] [Abstract][Full Text] [Related]
2. Cytokeratin markers in patients with prostatic diseases.
Wolff JM; Borchers H; Brehmer B; Brauers A; Jakse G
Anticancer Res; 1999; 19(4A):2649-52. PubMed ID: 10470212
[TBL] [Abstract][Full Text] [Related]
3. Serum concentrations of transforming growth factor-beta 1 in patients with benign and malignant prostatic diseases.
Wolff JM; Fandel TH; Borchers H; Jakse G
Anticancer Res; 1999; 19(4A):2657-9. PubMed ID: 10470214
[TBL] [Abstract][Full Text] [Related]
4. Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors.
Tarle M; Kovacić K; Kastelan M
Anticancer Res; 1993; 13(1):215-8. PubMed ID: 7682800
[TBL] [Abstract][Full Text] [Related]
5. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
Tarle M
Anticancer Res; 1993; 13(3):769-77. PubMed ID: 7686362
[TBL] [Abstract][Full Text] [Related]
6. Transforming growth factor-beta1 serum concentration in patients with prostatic cancer and benign prostatic hyperplasia.
Wolff JM; Fandel T; Borchers H; Brehmer B; Jakse G
Br J Urol; 1998 Mar; 81(3):403-5. PubMed ID: 9523660
[TBL] [Abstract][Full Text] [Related]
7. Metastatic workup of patients with prostate cancer employing alkaline phosphatase and skeletal alkaline phosphatase.
Wolff JM; Ittel TH; Borchers H; Boekels O; Jakse G
Anticancer Res; 1999; 19(4A):2653-5. PubMed ID: 10470213
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic validity of macrophage migration inhibitory factor in serum of patients with prostate cancer: a re-evaluation.
Michael A; Stephan C; Kristiansen G; Burckhardt M; Loening SA; Schnorr D; Jung K
Prostate; 2005 Jan; 62(1):34-9. PubMed ID: 15389818
[TBL] [Abstract][Full Text] [Related]
9. Cytokeratin 8/18 levels in patients with prostate cancer and benign prostatic hyperplasia.
Wolff JM; Borchers H; Brehmer B; Brauers A; Jakse G
Urol Int; 1998; 60(3):152-5. PubMed ID: 9644784
[TBL] [Abstract][Full Text] [Related]
10. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
11. Analysis of NK cell activity, lymphocyte reactivity to mitogens and serotest PSA and TPS values in patients with primary and disseminated prostate cancer, PIN and BPH.
Kastelan M; Kovacić K; Tarle R; Kraljić I; Tarle M
Anticancer Res; 1997; 17(3B):1671-5. PubMed ID: 9179216
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of tissue-polypeptide specific antigen (TPS) in bladder cancer.
Menendez V; Galan JA; Fernandez-Suarez A; Lopez S; Alcover J; Calpena R; Filella X
Anticancer Res; 2002; 22(6B):3713-6. PubMed ID: 12552981
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls.
Marszalek M; Wachter J; Ponholzer A; Leitha T; Rauchenwald M; Madersbacher S
Eur Urol; 2005 Jul; 48(1):34-9. PubMed ID: 15967249
[TBL] [Abstract][Full Text] [Related]
14. Accuracy of tissue polypeptide specific antigen (TPS) in the diagnosis of ovarian malignancy.
Padungsutt P; Thirapagawong C; Senapad S; Suphanit I
Anticancer Res; 2000; 20(2B):1291-5. PubMed ID: 10810437
[TBL] [Abstract][Full Text] [Related]
15. Metastatic workup of patients with prostate cancer employing skeletal alkaline phosphatase.
Wolff JM; Ittel TH; Boeckmann W; Habib FK; Jakse G
Anticancer Res; 1997; 17(4B):2995-7. PubMed ID: 9329584
[TBL] [Abstract][Full Text] [Related]
16. [Value of prostate specific antigen in early diagnosis of prostatic cancer].
Xiao LP; Bi XJ; Li YN; Chen XQ; Zhang XF; Yu XP; Liu G; Yang MC; Song Z
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jan; 27(1):107-8, 112. PubMed ID: 17259162
[TBL] [Abstract][Full Text] [Related]
17. The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia.
Nakamura T; Scorilas A; Stephan C; Jung K; Soosaipillai AR; Diamandis EP
Cancer Res; 2003 Oct; 63(19):6543-6. PubMed ID: 14559849
[TBL] [Abstract][Full Text] [Related]
18. [Changes of serum total PSA and free PSA in patients with prostate carcinoma and benign prostate hyperplasia].
Gao ZW; Liu G; Sheng BW
Ai Zheng; 2004 Jun; 23(6):701-3. PubMed ID: 15191675
[TBL] [Abstract][Full Text] [Related]
19. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
Scorilas A; Plebani M; Mazza S; Basso D; Soosaipillai AR; Katsaros N; Pagano F; Diamandis EP
Prostate; 2003 Feb; 54(3):220-9. PubMed ID: 12518327
[TBL] [Abstract][Full Text] [Related]
20. Reduced circulating androgen bioactivity in patients with prostate cancer.
Raivio T; Santti H; Schatzl G; Gsur A; Haidinger G; Palvimo JJ; Jänne OA; Madersbacher S
Prostate; 2003 May; 55(3):194-8. PubMed ID: 12692785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
